CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease (CMV-BMT)

H. Kim Lyerly

Status and phase: Terminated; Phase 1

Conditions: Allogeneic Stem Cell Transplantation

Treatments: Biological: CMV pp65 Specific T Cells

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00611637

4138-07-10R5

IND 11649

Details and patient eligibility

About

The purpose of this study is to determine the safety and feasibility of CMV specific, T cell adoptive immunotherapy in patients who have undergone allogeneic stem cell transplantation for malignant disease.

Full description

The primary purpose of this clinical trial is to evaluate the safety of this treatment.

Enrollment: 2 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Stratum 1: Subjects must be undergoing a non-myeloablative stem cell transplant from a 6/6 matched, sibling donor for the treatment of a malignancy
• Stratum 2: Subjects must be undergoing a non-myeloablative stem cell transplant from a 3/6, 4/6, or 5/6 matched, sibling donor for the treatment of a malignancy.
• Stratum 3: Subjects must be undergoing a myeloablative stem cell transplant from a 3/6, 4/6, or 5/6 matched, sibling donor for the treatment of a malignancy.
• Donor must be CMV sero-positive.
• Karnofsky performance status ≥ 70%.
• Subject and donor must be one of the following HLA types: HLA A*0201, HLA-A*0101, HLA-A*2402, HLA-B*0702, HLA-B*0801, HLA-B*35, HLA-DR*1, or HLA-DR*4.
• Availability of the stem cell donor to provide multiple PBMC samples for T-cell culture if needed. These samples could be obtained via a 90cc peripheral blood draw or through leukapheresis. Stem cell donor must satisfy BMT Program criteria for undergoing leukapheresis to provide DLI and consent to provide repeat leukapheresis if this is necessary.
• Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.
• Ability to return to Duke University Medical Center for adequate follow-up as required by this protocol.
• In order to receive their T cell infusions, subjects should be:
• At least 2 weeks from the time of their allogeneic stem cell transplant.
• Without Grade 3 or 4, non-hematologic, major organ toxicity within the preceding 1 week; all non major organ toxicities must have resolved to grade-2 or less.

Exclusion criteria

• Pregnant women and nursing mothers.
• Current or prior history of brain metastases.
• More than 12 months since their allogeneic stem cell re-infusion.
• HIV+, Hepatitis BsAg+, Hepatitis C Ab+

Trial design

2 participants in 1 patient group

1

Experimental group

Treatment:

Biological: CMV pp65 Specific T Cells